Although it has been shown that genetic manipulation of Notch components in bone cells can result in changes in Sclerostin production[103], whether the increase in osteocyte-derived Sclerostin induced by MM cells is secondary to Notch activation remains to be determined. This evidence concerns the gene SOST and Miyoshi myopathy.